Download PDF

Science China Life Sciences

, Volume 56, Issue 8, pp 739–744 | Cite as

O-glycan profiling of serum glycan for potential renal cancer biomarkers

Open Access
Research Paper
First Online:
Received:
Accepted:

Abstract

Serum was obtained from 25 male renal cell carcinoma (RCC) patients and 21 healthy males. O-glycans were released by a β-elimination reaction and purified by graphitized carbon cartridge solid phase extraction, then profiled by matrix-assisted laser desorption/ionisation-time of flight mass spectrometry. After noise removal and peak alignment, 1372 peaks were extracted from 200000 data points. Feature peaks were analyzed by calculation of differential sensitivity and specificity. The combination of two feature peaks was chosen as a biomarker and could clearly differentiate RCC and normal samples in our study group.

Keywords

mass spectrometry glycan renal cell carcinoma biomarkers 
Download to read the full article text

References

  1. 1.
    Gutwein P, Schramme A, Sinke N, et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer, 2009, 45: 478–489PubMedCrossRefGoogle Scholar
  2. 2.
    Baldewijns M M, van Vlodrop I J, Schouten L J, et al. Genetics and epigenetics of renal cell cancer. Biochim et Biophys Acta, 2008, 1785: 133–155Google Scholar
  3. 3.
    Zheng L G. Clinical value of IVU, CT and MRI in renal carcinoma. Chin Med Equip J, 2010, 8: 83–90Google Scholar
  4. 4.
    Pantuck A J, Zisman A, Belldegrun A S. The changing natural history of renal cell carcinoma. J Urol, 2001, 166: 1611–1623PubMedCrossRefGoogle Scholar
  5. 5.
    Drucker B J. Renal cell carcinoma: current status and future prospects, Cancer Treat Rev, 2005, 31: 536–545PubMedCrossRefGoogle Scholar
  6. 6.
    Taniguchi N. Toward cancer biomarker discovery using the glycomics approach, Proteomics, 2008, 16: 3205–3208CrossRefGoogle Scholar
  7. 7.
    Ohtsubo K, Marth J D. Glycosylation in cellular mechanisms of health and disease. Cell, 2006, 126: 855–867PubMedCrossRefGoogle Scholar
  8. 8.
    Alper J. Glycobiology. Turning sweet on cancer. Science, 2003, 301: 159–160PubMedCrossRefGoogle Scholar
  9. 9.
    Villanueva J. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Proteome Res, 2005, 4: 1060–1072PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Reis C A, Osorio H, Silva L, et al. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol, 2010, 63: 322–329PubMedCrossRefGoogle Scholar
  11. 11.
    Ishizuka A, Hashimto Y, Naka R, et al. Accumulation of free complex-type N-glycans in MKN7 and MKN45 stomach. Biochem J, 2008, 413: 227–237PubMedCrossRefGoogle Scholar
  12. 12.
    Kirmiz C, Li B, An H J, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics, 2007, 6: 43–55PubMedCrossRefGoogle Scholar
  13. 13.
    Kyselova Z, Mechref Y, Al Bataineh M M, et al. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res, 2007, 6: 1822–1832PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Perret A G, Clemencon A, Li G, et al. Differential expression of prognostic markers in histological subtypes of papillary renal cell carcinoma. BJU Int, 2008, 102: 183–187PubMedCrossRefGoogle Scholar
  15. 15.
    Aubert S, Fauquette V, Hémon B, et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res, 2009, 69: 5707–5715PubMedCrossRefGoogle Scholar
  16. 16.
    Morelle W, Michalski J C. Analysis of protein glycosylation by mass spectrometry. Nat Protoc, 2007, 2: 1585–1602PubMedCrossRefGoogle Scholar
  17. 17.
    Diamandis E P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol Cell Proteomics, 2004, 3: 367–378PubMedCrossRefGoogle Scholar
  18. 18.
    Morelle W, Canis K, Chirat F, et al. The use of mass spectrometry for the proteomic analysis of glycosylation. Proteomics, 2006, 6: 3993–4015PubMedCrossRefGoogle Scholar
  19. 19.
    McLerran D F, Feng Z, Semmes O J, et al. Signal detection in high-resolution mass spectrometry data. J Proteome Res, 2008, 7: 276–285PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang S, DeGraba T J, Wang H, et al. A novel peak detection approach with chemical noise removal using short-time FFT for prOTOF MS data. Proteomics, 2009, 9: 3833–3842PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Yang C, He Z, Yu W. Comparison of public peak detection algorithms for MALDI mass spectrometry data analysis. BMC Bioinformatics, 2009, 10: 4–17PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Author(s) 2013

Authors and Affiliations

  1. 1.Department of UrologyChangzheng Hospital of Second Military Medical UniversityShanghaiChina
  2. 2.State Key Laboratory of Proteomics, Beijing Proteome Research CenterBeijing Institute of Radiation MedicineBeijingChina
  3. 3.Shanghai Key Laboratory of Functional Materials Chemistry, School of Chemistry and Molecular EngineeringEast China University of Science and TechnologyShanghaiChina
  4. 4.Department of Automatic Control, College of Mechatronics and AutomationNational University of Defense TechnologyChangshaChina
  5. 5.Laboratory of Systems Biology, Institutes of Biomedical SciencesFudan UniversityShanghaiChina

Personalised recommendations